Baxter, Moderna in Deal for Fill/Finish Manufacturing of Covid Vaccine in U.S.
March 08 2021 - 09:47AM
Dow Jones News
By Michael Dabaie
Baxter International Inc. and Moderna Inc. said they are in an
agreement for Baxter BioPharma Solutions to provide fill/finish
sterile manufacturing services and supply packaging for about 60
million to 90 million doses of the Moderna Covid-19 Vaccine in
2021.
Baxter's BioPharma Solutions business is a contract
manufacturing organization that specializes in injectable
pharmaceuticals, including vaccines.
The manufacturing of the Moderna Covid-19 vaccine would take
place at the BioPharma Solutions fill/finish sterile manufacturing
facilities in Bloomington, Ind.
The companies didn't disclose additional details of the
agreement.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 08, 2021 09:32 ET (14:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.